Cassava Sciences(SAVA) - 2024 Q2 - Quarterly Results

EXHIBIT 99.1 Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates $207.3 Million in Cash and Cash Equivalents at June 30, 2024. Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution. Conference Webcast Scheduled for Today at 8:30AM ET. AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on a novel treatment for Alzheimer's disease, today repor ...